ELOX · Eloxx Pharmaceuticals, Inc.

Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock.

The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.

The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock.

The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.

The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock.

The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium.

The option was granted on September 19, 2025 and was subject to a performance-based vesting condition that was satisfied on June 10, 2026. The option will vest as to 1/36 on July 31, 2026, with the remaining options vesting in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuing service on each such vesting date.

Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock.

The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium.

The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Pursuant to the terms of that certain Amended and Restated Pre-Funded Warrant to Purchase Common Stock, dated as of April 27, 2026, Coastlands Capital Partners LP (the "Partnership"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer.

Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of the Partnership. Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.

Pursuant to the terms of the pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants"), Domicilium Real Estate Fund III LP (the "Fund"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer.

These securities reflect a 11 for 1 reverse stock split effective May 29, 2026.

The securities are owned directly by the Fund and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (iii) Daniel Simon, the managing member of Domicilium and the General Partner.

The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Pursuant to the terms of the pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants"), Domicilium Real Estate Fund III LP (the "Fund"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer.

These securities reflect a 11 for 1 reverse stock split effective May 29, 2026.

The securities are owned directly by the Fund and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (iii) Daniel Simon, the managing member of Domicilium and the General Partner.

Pursuant to the terms of that certain Amended and Restated Pre-Funded Warrant to Purchase Common Stock, dated as of April 27, 2026, Coastlands Capital Partners LP (the "Partnership"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer.

The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of the Partnership. Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.

The option vests as follows: (i) as to 1,736,275 shares, vested 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; (ii) as to 612,245 shares, vested 1/36 on January 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; and (iii) as to 1,248,570 shares, vested 1/36 on March 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vested as to 50% on the first anniversary of January 24, 2024, and the remaining amount vested in two equal annual installments thereafter.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

The option vests as follows: (i) as to 1,736,275 shares, vested 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; (ii) as to 612,245 shares, vested 1/36 on January 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; and (iii) as to 1,248,570 shares, vested 1/36 on March 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Represents a grant of restricted stock units ("RSUs") that was fully vested upon grant.

The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise.

The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise.

The option was granted on August 23, 2023 and was scheduled to vest subject to certain performance criteria, which the Board waived in connection with the exercise.

The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.

The reporting person agreed to cancellation of an option granted to him on January 25, 2023 in exchange for a new option having a lower exercise price.

The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise.

The reporting person agreed to cancellation of an option granted to him on February 6, 2022 in exchange for a new option having a lower exercise price.

The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise.

The reporting person agreed to cancellation of an option granted to him on April 1, 2021 in exchange for a new option having a lower exercise price.

The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter.

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split.

The reporting person agreed to cancellation of an option granted to him on May 18, 2021 in exchange for a new option having a lower exercise price.

The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter.

This restricted stock award was made under the Issuer's 2018 Equity Incentive Plan and vests as to 25% on October 16, 2025 and in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.

The reporting person agreed to cancellation of an option granted to him on January 25, 2023 in exchange for a new option having a lower exercise price.

The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise.

This restricted stock grant was made pursuant to the Issuer's 2018 Equity Incentive Plan and vests as to 50% of the shares on October 16, 2025 and in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split.

The reporting person agreed to cancellation of an option granted to him on February 6, 2022 in exchange for a new option having a lower exercise price.

The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise.

This restricted stock grant was made pursuant to the Issuer's 2018 Equity Incentive Plan and vests as to 50% of the shares on October 16, 2025 and in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

This restricted stock grant was made pursuant to the Issuer's 2018 Equity Incentive Plan and vests as to 50% of the shares on October 16, 2025 and in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.